MKC-1: Phase I start

Next quarter, EntreMed will start a dose-escalation, U.S. Phase I trial to evaluate continuous-dosing of oral MKC-1 in patients with refractory solid tumors. EntreMed has exclusive rights to MKC-1 fro...